BACKGROUND: Influenza vaccines may be reformulated annually because of antigenic drift in influenza viruses. However, the relationship between antigenic characteristics of circulating viruses and vaccine effectiveness (VE) is not well understood. We conducted an assessment of the effectiveness of US influenza vaccines during the 2010-2011 season. METHODS: We performed a case-control study comparing vaccination histories between subjects with acute respiratory illness with positive real-time reverse transcription polymerase chain reaction for influenza and influenza test-negative controls. Subjects with acute respiratory illness of ≤7 days duration were enrolled in hospitals, emergency departments, or outpatient clinics in communities in 4 states. History of immunization with the 2010-2011 vaccine was ascertained from vaccine registries or medical records. Vaccine effectiveness was estimated in logistic regression models adjusted for study community, age, race, insurance status, enrollment site, and presence of a high-risk medical condition. RESULTS: A total of 1040 influenza-positive cases and 3717 influenza-negative controls were included from the influenza season, including 373 cases of influenza A(H1N1), 334 cases of influenza A(H3N2), and 333 cases of influenza B. Overall adjusted VE was 60% (95% confidence interval [CI], 53%-66%). Age-specific VE estimates ranged from 69% (95% CI, 56%-77%) in children aged 6 months-8 years to 38% (95% CI, -16% to 67%) in adults aged ≥65 years. CONCLUSIONS: The US 2010-2011 influenza vaccines were moderately effective in preventing medically attended influenza during a season when all 3 vaccine strains were antigenically similar to circulating viruses. Continued monitoring of influenza vaccines in all age groups is important, particularly as new vaccines are introduced.
BACKGROUND: Influenza vaccines may be reformulated annually because of antigenic drift in influenza viruses. However, the relationship between antigenic characteristics of circulating viruses and vaccine effectiveness (VE) is not well understood. We conducted an assessment of the effectiveness of US influenza vaccines during the 2010-2011 season. METHODS: We performed a case-control study comparing vaccination histories between subjects with acute respiratory illness with positive real-time reverse transcription polymerase chain reaction for influenza and influenza test-negative controls. Subjects with acute respiratory illness of ≤7 days duration were enrolled in hospitals, emergency departments, or outpatient clinics in communities in 4 states. History of immunization with the 2010-2011 vaccine was ascertained from vaccine registries or medical records. Vaccine effectiveness was estimated in logistic regression models adjusted for study community, age, race, insurance status, enrollment site, and presence of a high-risk medical condition. RESULTS: A total of 1040 influenza-positive cases and 3717 influenza-negative controls were included from the influenza season, including 373 cases of influenza A(H1N1), 334 cases of influenza A(H3N2), and 333 cases of influenza B. Overall adjusted VE was 60% (95% confidence interval [CI], 53%-66%). Age-specific VE estimates ranged from 69% (95% CI, 56%-77%) in children aged 6 months-8 years to 38% (95% CI, -16% to 67%) in adults aged ≥65 years. CONCLUSIONS: The US 2010-2011 influenza vaccines were moderately effective in preventing medically attended influenza during a season when all 3 vaccine strains were antigenically similar to circulating viruses. Continued monitoring of influenza vaccines in all age groups is important, particularly as new vaccines are introduced.
Authors: R B Belshe; P M Mendelman; J Treanor; J King; W C Gruber; P Piedra; D I Bernstein; F G Hayden; K Kotloff; K Zangwill; D Iacuzio; M Wolff Journal: N Engl J Med Date: 1998-05-14 Impact factor: 91.245
Authors: Evan W Orenstein; Gaston De Serres; Michael J Haber; David K Shay; Carolyn B Bridges; Paul Gargiullo; Walter A Orenstein Journal: Int J Epidemiol Date: 2007-04-02 Impact factor: 7.196
Authors: Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor Journal: N Engl J Med Date: 2007-02-15 Impact factor: 91.245
Authors: Arnold S Monto; Suzanne E Ohmit; Joshua G Petrie; Emileigh Johnson; Rachel Truscon; Esther Teich; Judy Rotthoff; Matthew Boulton; John C Victor Journal: N Engl J Med Date: 2009-09-24 Impact factor: 91.245
Authors: Edward A Belongia; Burney A Kieke; James G Donahue; Robert T Greenlee; Amanda Balish; Angie Foust; Stephen Lindstrom; David K Shay Journal: J Infect Dis Date: 2009-01-15 Impact factor: 5.226
Authors: Danuta M Skowronski; Gaston De Serres; Jim Dickinson; Martin Petric; Annie Mak; Kevin Fonseca; Trijntje L Kwindt; Tracy Chan; Nathalie Bastien; Hugues Charest; Yan Li Journal: J Infect Dis Date: 2009-01-15 Impact factor: 5.226
Authors: Marie Smithgall; Celibell Y Vargas; Carrie Reed; Lyn Finelli; Philip LaRussa; Elaine L Larson; Lisa Saiman; Melissa S Stockwell Journal: Clin Infect Dis Date: 2015-09-28 Impact factor: 9.079
Authors: Suzanne E Ohmit; Mark G Thompson; Joshua G Petrie; Swathi N Thaker; Michael L Jackson; Edward A Belongia; Richard K Zimmerman; Manjusha Gaglani; Lois Lamerato; Sarah M Spencer; Lisa Jackson; Jennifer K Meece; Mary Patricia Nowalk; Juhee Song; Marcus Zervos; Po-Yung Cheng; Charles R Rinaldo; Lydia Clipper; David K Shay; Pedro Piedra; Arnold S Monto Journal: Clin Infect Dis Date: 2013-11-13 Impact factor: 9.079
Authors: Kate Russell; Jessie R Chung; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Brendan Flannery Journal: Vaccine Date: 2018-02-28 Impact factor: 3.641
Authors: Suzanne E Ohmit; Joshua G Petrie; Ryan E Malosh; Alicia M Fry; Mark G Thompson; Arnold S Monto Journal: J Infect Dis Date: 2014-11-21 Impact factor: 5.226
Authors: Núria Torner; Ana Martínez; Luca Basile; M Angeles Marcos; Andrés Antón; M Mar Mosquera; Ricard Isanta; Carmen Cabezas; Mireia Jané; Angela Domínguez; The Pidirac Sentinel Surveillance Program Of Catalonia Journal: Hum Vaccin Immunother Date: 2014-11-01 Impact factor: 3.452
Authors: Andrea S Gershon; Hannah Chung; Joan Porter; Michael A Campitelli; Sarah A Buchan; Kevin L Schwartz; Natasha S Crowcroft; Aaron Campigotto; Jonathan B Gubbay; Timothy Karnauchow; Kevin Katz; Allison J McGeer; J Dayre McNally; David C Richardson; Susan E Richardson; Laura C Rosella; Andrew E Simor; Marek Smieja; George Zahariadis; Jeffrey C Kwong Journal: J Infect Dis Date: 2020-01-01 Impact factor: 5.226
Authors: Mark G Thompson; Jessie Clippard; Joshua G Petrie; Michael L Jackson; Huong Q McLean; Manjusha Gaglani; Evelyn C Reis; Brendan Flannery; Arnold S Monto; Lisa Jackson; Edward A Belongia; Kempapura Murthy; Richard K Zimmerman; Swathi Thaker; Alicia M Fry Journal: Pediatr Infect Dis J Date: 2016-03 Impact factor: 2.129